Fina Biosolutions specializes in the development and production of carrier proteins and bioconjugation technologies aimed at enhancing the efficacy of conjugate vaccines, particularly for emerging markets. Their key products include CRM 197 and rTTHc, which are produced using a proprietary E. coli strain and are available for both preclinical and clinical applications. The company emphasizes its expertise in conjugation chemistry, offering a range of functionalized dextrans, including amino and fluorescent dextrans, as well as mono- and multi-functionalized variants. These products are designed to support vaccine manufacturers in creating affordable and effective conjugate vaccines.

In addition to their product offerings, Fina Biosolutions provides a variety of services tailored to the needs of the biotech and vaccine industries. Their services encompass bioconjugation, protein characterization, and analytical assessments, which include multi-angle light scattering and immunoassay design. The company is committed to advancing vaccine development through its consulting services and training programs, ensuring that emerging market manufacturers have the necessary tools and knowledge to produce high-quality conjugate vaccines.

United States

Fina Biosolutions, LLC was founded in 2006 by Dr. Andrew Lees with an initial focus on helping emerging market vaccine manufacturers learn to make affordable conjugate vaccines. The company offers bioconjugation, protein expression, purification, immunoassay design, analytics, training, and consulting services.

Fina Biosolutions, 9420 Key West Avenue, Suite 550, Rockville, MD 20850, United States

Fina Biosolutions

Company Details